Abstract: An embodiment of a robotic fabric has a first fabric layer and an actuator that is configured to have a first state and a second state. A property of the first fabric layer is different when the actuator is in the first state as compared to the property of the first fabric layer when the actuator is in the second state.
Abstract: The present disclosure provides a high-power-density power converter topology with a common neutral between its input and output AC ports while having a single DC bus. The topology may also be embodied as an online uninterruptible power supply (UPS). The presently-disclosed topology enables high power density by utilizing half-bridge switch structures suitable for MHz-frequency operation.
Type:
Grant
Filed:
September 6, 2019
Date of Patent:
July 5, 2022
Assignees:
Cornell University, The Regents of the University of Colorado, a body corporate
Abstract: The present disclosure describes approaches to voice restoration using personal devices that detect surface electromyographic (sEMG) signals from articulatory muscles for the recognition of silent speech in a patient (such as a patient with total laryngectomy, on voice rest, etc.). A personal device may comprise a cutaneous sensor unit and a control module that wirelessly transmits signals to a computing device capable of, for example, applying a predictive model to signals to generate text or synthesize speech. Methods and systems for training and applying predictive models, and fabricating personal devices, are disclosed.
Abstract: Gallium nitride high-electron-mobility transistors (GaN HEMTs) are at a point of rapid growth in defense (radar, SATCOM) and commercial (5G and beyond) industries. This growth also comes at a point at which the standard GaN heterostructures remain unoptimized for maximum performance. For this reason, the shift to the aluminum nitride (AlN) platform is disclosed. AlN allows for smarter, highly-scaled heterostructure design that improves the output power and thermal management of GaN amplifiers. Beyond improvements over the incumbent amplifier technology, AlN allows for a level of integration previously unachievable with GaN electronics. State-of-the-art high-current p-channel FETs, mature filter technology, and advanced waveguides, all monolithically integrated with an AlN/GaN/AlN HEMT, is made possible with aluminum nitride. It is on this AlN platform that nitride electronics may maximize their full high-power, highspeed potential for mm-wave communication and high-power logic applications.
Type:
Application
Filed:
December 17, 2021
Publication date:
June 23, 2022
Applicant:
Cornell University
Inventors:
Austin Hickman, Reet Chaudhuri, James C. M. Hwang, Huili Grace Xing, Debdeep Jena
Abstract: The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue overexpressing PSMA. The compounds are of Formula I or a pharmaceutically acceptable salt thereof, wherein one of R1, R2, and R3 is and of Formula IV or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
July 30, 2021
Publication date:
June 23, 2022
Applicant:
Cornell University
Inventors:
John W. Babich, Jasmes M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala
Abstract: A meta-optical device, which imparts a phase delay to incident light of a wavelength band, includes: a first electrode and a second electrode spaced apart from each other; a liquid crystal layer between the first electrode and the second electrode; a meta-surface layer located within the liquid crystal layer and including a plurality of nanostructures each having a shape dimension smaller than a center wavelength of the wavelength band; and a voltage device configured to apply a voltage between the first electrode and the second electrode. The meta-optical device may exhibit an electrically controlled variable focal length.
Type:
Application
Filed:
December 15, 2021
Publication date:
June 16, 2022
Applicants:
Samsung Electronics Co., Ltd., Cornell University
Abstract: The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.
Type:
Application
Filed:
February 23, 2022
Publication date:
June 16, 2022
Applicant:
Cornell University
Inventors:
John W. Babich, Justin Wilson, Nikki Thiele, James Kelly, Shashikanth Ponnala
Abstract: The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.
Type:
Application
Filed:
February 23, 2022
Publication date:
June 9, 2022
Applicant:
Cornell University
Inventors:
John W. Babich, Justin WILSON, Nikki THIELE, James KELLY, Shashikanth PONNALA
Abstract: Disclosed herein are actuators and methods of making and actuating the same. Such actuators may comprise a body having a cavity, a membrane configured to cooperate with the cavity to form a combustion chamber, an inlet channel in fluid communication with the combustion chamber, an ignitor operable to ignite a combustible gas contained within the combustion chamber, and an outlet channel in fluid communication with the combustion chamber. The membrane may be configured to move in response to a change in pressure within the combustion chamber.
Type:
Grant
Filed:
August 19, 2020
Date of Patent:
June 7, 2022
Assignee:
Cornell University
Inventors:
Ronald Heisser, Robert Shepherd, Cameron Aubin
Abstract: Among the various aspects of the present disclosure is the provision of compositions of isotope-ligand complexes, methods of use thereof, and methods of chelating isotopes. The present disclosure also provides for methods for modulating ion channel transportation of radiopharmaceuticals. For example, the inhibition of radiopharmaceutical transport comprises administering an ion channel transport modulating or inhibiting agent (e.g., a calcium channel inhibitor) in an amount effective to inhibit gastrointestinal uptake.
Type:
Application
Filed:
March 1, 2020
Publication date:
May 19, 2022
Applicants:
Washington University, Cornell University
Inventors:
Daniel THOREK, Diane ABOU, Justin WILSON, Nikki THIELE
Abstract: Described herein are methods for treating B cell proliferative disorders, in an individual in need thereof. The methods include administering to an individual in need thereof a Btk inhibitor (e.g., ibrutinib), in combination with a CDK4 inhibitor (e.g., palbociclib).
Abstract: A method of preventing or treating a subject suffering from Clostiridium difficile infection or its associated symptom includes administering a therapeutic effective amount of a HMGB1 inhibitor to the subject. A method of inhibiting toxin-induced cytotoxic effect in colon cells includes contacting the colon cells with an effective amount of a HMGB1 inhibitor.
Type:
Grant
Filed:
August 15, 2019
Date of Patent:
May 3, 2022
Assignees:
City University of Hong Kong, Cornell University
Abstract: The present disclosure relates generally to compositions and methods for the treatment of eye diseases (e.g., retinopathies), and more particularly, to treatment of eye diseases associated with retinal cell lipofuscin accumulation.
Type:
Application
Filed:
March 3, 2020
Publication date:
April 21, 2022
Applicant:
Cornell University
Inventors:
Marcelo M. Nociari, Enrique Rodriguez Boulan
Abstract: Provided are a superlattice structure including a two-dimensional material and a device including the superlattice structure. The superlattice structure may include at least two different two-dimensional (2D) materials bonded to each other in a lateral direction, and an interfacial region of the at least two 2D materials may be strained. The superlattice structure may have a bandgap adjusted by the interfacial region that is strained. The at least two 2D materials may include first and second 2D materials. The first 2D material may have a first bandgap in an intrinsic state thereof. The second 2D material may have a second bandgap in an intrinsic state thereof. An interfacial region of the first and second 2D materials and an adjacent region may have a third bandgap between the first bandgap and the second bandgap.
Type:
Application
Filed:
November 1, 2021
Publication date:
April 7, 2022
Applicants:
Samsung Electronics Co., Ltd., THE UNIVERSITY OF CHICAGO, Center for Technology Licensing at Cornell University
Abstract: The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer. The compounds are represented by the following formula: (I) or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
April 5, 2018
Date of Patent:
March 29, 2022
Assignee:
Cornell University
Inventors:
John W. Babich, James M. Kelly, Alejandro Amor-Coarasa, Shashikanth Ponnala
Abstract: The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.
Type:
Grant
Filed:
November 20, 2019
Date of Patent:
March 22, 2022
Assignee:
Cornell University
Inventors:
John W. Babich, Justin Wilson, Nikki Thiele, James Kelly, Shashikanth Ponnala
Abstract: A heterostructure includes a substrate exhibiting a piezoelectric effect, and a magnetostrictive film supported by the substrate. The magnetostrictive film includes an iron-gallium alloy. The iron-gallium alloy has a gallium composition greater than 20%.
Type:
Grant
Filed:
February 7, 2020
Date of Patent:
March 15, 2022
Assignees:
The Regents of the University of Michigan, Cornell University
Inventors:
John Thomas Heron, Peter Benjamin Meisenheimer, Darrell G. Schlom, Rachel Steinhardt
Abstract: Systems and methods are disclosed for optimizing a sub-sampling pattern for efficient capture of a sub-sampled image to be reconstructed to form a high-resolution image, in a data-driven fashion. For example, Magnetic Resonance Imaging (MRI) scans can be accelerated by under-sampling in k-space (i.e., the Fourier domain). Since the reconstruction model's success depends on the sub-sampling pattern, optimization of the sub-sampling pattern can be combined with optimization of the model, for a given sparsity constraint, using an end-to-end learning operation. A machine-learning model may be trained using full-resolution training data that are under-sampled retrospectively, yielding a sub-sampling pattern and reconstruction model that are customized to the type of images represented in the training data.
Abstract: A device and method for terahertz signal generation are disclosed. Oscillators are arranged in a two-dimensional array, each oscillator connected to a corresponding antenna. Each oscillator is unidirectional connected to its adjacent oscillators by a phase shifter. A method for generating a steerable terahertz signal utilizes an array of oscillators connected by corresponding phase shifters. A terahertz signal having a fundamental frequency is generated using the array. The phase shift of one or more of the phase shifters is varied in order to vary the fundamental frequency and/or steer the signal generated by the array.
Abstract: The present invention relates to an exceptionally broad and potent neutralizing antibody which may comprise cross-clade neutralizing coverage of 83% at a median IC50 of 0.003 ?g/ml, compositions containing the same and uses thereof.
Type:
Grant
Filed:
December 24, 2019
Date of Patent:
April 19, 2022
Assignees:
International AIDS Vaccine Initiative, The Scripps Research Institute, Cornell University
Inventors:
Dennis R. Burton, Marit J. Van Gils, Wayne Koff, Pascal R. G. Poignard, Rogier W. Sanders, Melissa D. J. S. Simek-Lemos, Devin Sok